Bone Biologics (NASDAQ:BBLG) Stock Price Down 0.8% – Here’s What Happened

Shares of Bone Biologics Corp. (NASDAQ:BBLG) fell 0.8% on Tuesday . The company traded as low as $2.38 and last traded at $2.45. 15,117 shares were traded during trading, a decline of 89% from the average session volume of 143,352 shares. The stock had previously closed at $2.47.

Analyst Upgrades and Downgrades

A number of research analysts have commented on BBLG shares. Wall Street Zen upgraded Bone Biologics from a “sell” rating to a “hold” rating in a research note on Sunday, September 28th. Weiss Ratings restated a “sell (e+)” rating on shares of Bone Biologics in a research note on Tuesday, October 14th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Bone Biologics Price Performance

The business has a 50-day simple moving average of $2.32 and a two-hundred day simple moving average of $3.44.

Bone Biologics (NASDAQ:BBLG) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($1.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.75). Sell-side analysts expect that Bone Biologics Corp. will post -5 EPS for the current fiscal year.

About Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.